Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
被引用次数：257 相关文章

Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw… - Trends in …, 2022 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but
most'immune-cold'solid tumors are not responsive. The diversity of immune evasion …

Turning cold tumors hot: from molecular mechanisms to clinical applications.

J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - europepmc.org
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but
most'immune-cold'solid tumors are not responsive. The diversity of immune evasion …

Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - Elsevier
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in Immunology, 2022 - Elsevier
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …